Trader's blog
J&J strikes $6.5 billion deal for autoimmune disease specialist Momenta

Johnson & Johnson on Wednesday agreed to buy Momenta Pharmaceuticals Inc for about $6.5 billion to add muscle to its portfolio of drugs for hard-to-treat autoimmune diseases.

The deal gives J&J’s Janssen unit access to Momenta’s experimental therapy, nipocalimab, being tested for myasthenia gravis, a neuromuscular disease that causes weakness in muscles, and other diseases where the immune system attacks the body.

J&J hopes to get the drug approved to treat several conditions and eventually bring in blockbuster sales, as the company seeks to bulk up its largest business with a new class of medicines.

“Janssen will have the potential to introduce multiple launches, many as first-in-class indications with potential for significant peak year sales, some of which could exceed $1 billion,” Johnson & Johnson said in a statement.

Shares of Cambridge, Massachusetts-based Momenta were up 68.8% at $52, just a hair’s breadth away from the offer price of $52.50.

“We find the deal modestly surprising as we see every one of Momenta’s assets as somewhat tricky to develop,” said BTIG analyst Thomas Shrader, adding it was hard to imagine a higher bid for Momenta.

J&J’s offer for Momenta comes just days after France’s Sanofi struck a $3.7 billion deal to buy Principia Biopharma Inc for its pipeline of autoimmune disease treatments.

J&J in recent years has sold some divisions such as the one which makes medical devices for diabetes care as it sharpens focus on better-performing businesses like cancer treatments.

The company, which is also one of the drugmakers racing to develop a vaccine for the coronavirus, recently signed deals with the United States and Britain for future doses of the potential vaccine.

Leave comment

Your email address will not be published. Required fields are marked with *.


Leave comment

Your email address will not be published. Required fields are marked with *.